Astellas Pharma (ALPMY) News Today $9.85 +0.13 (+1.34%) As of 03:58 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Astellas Pharma (OTCMKTS:ALPMY) Stock Passes Above 50-Day Moving Average - Should You Sell?Astellas Pharma (OTCMKTS:ALPMY) Stock Price Passes Above Fifty Day Moving Average - Time to Sell?March 11 at 3:42 AM | marketbeat.comJ.P. Morgan Remains a Hold on Astellas Pharma (ALPMF)March 8, 2025 | markets.businessinsider.comAstellas and Yaskawa form JV for cell therapy product manufactureMarch 7, 2025 | finance.yahoo.comAstellas and YASKAWA form JV focused on cell therapy manufacturingMarch 6, 2025 | msn.comAstellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy ManufacturingMarch 6, 2025 | finance.yahoo.comAstellas Pharma (OTCMKTS:ALPMY) Stock Crosses Below 200-Day Moving Average - Here's WhyAstellas Pharma (OTCMKTS:ALPMY) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?March 2, 2025 | marketbeat.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest UpdateAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 47,200 shares, a decline of 49.0% from the January 31st total of 92,500 shares. Based on an average trading volume of 625,500 shares, the short-interest ratio is currently 0.1 days.March 2, 2025 | marketbeat.comAstellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator PrizeFebruary 27, 2025 | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?Astellas Pharma (OTCMKTS:ALPMY) Shares Pass Below 200-Day Moving Average - What's Next?February 22, 2025 | marketbeat.comAstellas Pharma Inc.: U.S. FDA Approves Expanded Label for Astellas' IZERVAY (avacincaptad pegol intravitreal solution) for Geographic AtrophyFebruary 13, 2025 | finanznachrichten.deShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Increases By 132.4%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 92,500 shares, a growth of 132.4% from the January 15th total of 39,800 shares. Based on an average daily trading volume, of 497,000 shares, the short-interest ratio is presently 0.2 days.February 13, 2025 | marketbeat.comU.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic AtrophyFebruary 12, 2025 | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Below 50 Day Moving Average - Here's WhyAstellas Pharma (OTCMKTS:ALPMY) Shares Pass Below 50 Day Moving Average - What's Next?February 12, 2025 | marketbeat.comPfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. ChemoFebruary 11, 2025 | finance.yahoo.comAstellas seeks conditional approval for GA treatment in JapanFebruary 5, 2025 | finance.yahoo.comAstellas Pharma Submits NDA For Avacincaptad Pegol For Geographic Atrophy In JapanFebruary 5, 2025 | markets.businessinsider.comAstellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in JapanFebruary 5, 2025 | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) Releases Earnings ResultsAstellas Pharma (OTCMKTS:ALPMY - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.30 EPS for the quarter. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%.February 4, 2025 | marketbeat.comAstellas Makes Announcement about Management StructureFebruary 4, 2025 | prnewswire.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Growth in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 39,800 shares, an increase of 26.3% from the December 31st total of 31,500 shares. Based on an average daily trading volume, of 569,300 shares, the days-to-cover ratio is currently 0.1 days.February 1, 2025 | marketbeat.comJefferies Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)January 25, 2025 | markets.businessinsider.comAstellas Pharma (OTCMKTS:ALPMY) Hits New 12-Month Low - Here's What HappenedAstellas Pharma (OTCMKTS:ALPMY) Reaches New 52-Week Low - What's Next?January 24, 2025 | marketbeat.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Declines By 58.7%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 31,500 shares, a decrease of 58.7% from the December 15th total of 76,200 shares. Based on an average daily volume of 787,700 shares, the days-to-cover ratio is presently 0.0 days.January 14, 2025 | marketbeat.comFDA Accepts Astellas Pharma's Revised SNDA For IZERVAY In Geographic Atrophy TreatmentJanuary 9, 2025 | markets.businessinsider.comAstellas Pharma : China's NMPA Approves VYLOY For Advanced Gastric/Gastroesophageal Junction CancerJanuary 5, 2025 | markets.businessinsider.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Increases By 150.7%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 76,200 shares, an increase of 150.7% from the November 30th total of 30,400 shares. Based on an average daily volume of 559,900 shares, the days-to-cover ratio is currently 0.1 days.December 27, 2024 | marketbeat.comAxcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein DegradersDecember 25, 2024 | businesswire.comAstellas and Sangamo sign capsid deal for neurological diseasesDecember 20, 2024 | msn.comAstellas Pharma (OTCMKTS:ALPMY) Share Price Passes Below 200-Day Moving Average - What's Next?Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?December 19, 2024 | marketbeat.comAstellas In Deal With Sangamo For STAC-BBB Capsid To Deliver Genomic MedicinesDecember 19, 2024 | markets.businessinsider.comAstellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for ThemselvesDecember 5, 2024 | prnewswire.comAstellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure ManagementNovember 20, 2024 | prnewswire.comAstellas Faces FDA Setback on IZERVAY ApplicationNovember 18, 2024 | markets.businessinsider.comAstellas Pharma H1 Profit Rises; Lifts FY24 OutlookOctober 30, 2024 | markets.businessinsider.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Growth in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totalling 45,100 shares, an increase of 16.2% from the September 30th total of 38,800 shares. Based on an average trading volume of 182,400 shares, the days-to-cover ratio is presently 0.2 days.October 29, 2024 | marketbeat.comAstellas Pharma Withdraws EU Application for Key DrugOctober 28, 2024 | markets.businessinsider.comBernstein Releases a Buy Rating on Astellas Pharma (ALPMF)October 23, 2024 | markets.businessinsider.comAstellas Pharma’s VYLOY Gains FDA Approval for Cancer TreatmentOctober 21, 2024 | markets.businessinsider.comAstellas Pharma's Cancer Drug Vyloy Gets FDA ApprovalOctober 19, 2024 | marketwatch.comAstellas Pharma's VYLOY Receives FDA Approval For Treatment Of Advanced Gastric And GEJ CancerOctober 19, 2024 | markets.businessinsider.comAstellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ CancerOctober 18, 2024 | prnewswire.comFDA approves Astellas' gastric cancer therapyOctober 18, 2024 | reuters.comAstellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on MenopauseOctober 10, 2024 | prnewswire.comAstellas Receives Option To License AVB-101 - Quick FactsOctober 9, 2024 | markets.businessinsider.comAstellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other IndicationsOctober 8, 2024 | prnewswire.comSinglera Genomics and Astellas Present Methylation-based Organ Toxicity Detection at 2024 JSOT Annual MeetingOctober 1, 2024 | businesswire.comPoseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B AdvancementSeptember 30, 2024 | seekingalpha.comHere are the Medicare Part D drugs expected to face 2025 price negotiationsSeptember 29, 2024 | seekingalpha.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Decrease in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 10,500 shares, a drop of 75.4% from the August 31st total of 42,600 shares. Based on an average daily volume of 201,200 shares, the days-to-cover ratio is presently 0.1 days.September 25, 2024 | marketbeat.comAstellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction CancerSeptember 20, 2024 | prnewswire.com Remove Ads Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address ALPMY Media Mentions By Week ALPMY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALPMY News Sentiment▼0.340.79▲Average Medical News Sentiment ALPMY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALPMY Articles This Week▼62▲ALPMY Articles Average Week Remove Ads Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TAK News Today UCBJF News Today UCBJY News Today ALNY News Today BAYRY News Today ONC News Today RPRX News Today MKKGY News Today MKGAF News Today TEVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ALPMY) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredWarning: What they're not telling you about these recent selloffsIn light of massive recent selloffs... our senior analyst Dan Ferris has issued a new warning for the American...Stansberry Research | SponsoredSilent Raid on IRAs and 401(k)s Begins—Are You Next?Look around—everything feels oddly steady. Gas prices aren't skyrocketing. Banks aren't collapsing. The mar...Genesis Gold Group | SponsoredMagnificent 7 wipeout: What's next?A massive wave of volatility is sweeping the stock market... After the recent selloff, the "Magnificent Sev...Chaikin Analytics | SponsoredWarren Buffet Just Made a $334 Billion BetDebt is out of control. Inflation is creeping back. And a major market downturn could be right around the corn...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALPMY Stock Alerts